Immunophotonics, Inc. — SEC Form D Filing

Immunophotonics, Inc. filed an SEC Form D on September 4, 2026, reporting $10.15M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
September 4, 2026
Amount reported
$10.15M
Round stage
Series B because a ten million dollar equity raise typically supports mid-stage clinical trials and pipeline expansion for biotechnology corporations.
Industry
Pharmaceuticals
Website
https://www.immunophotonics.com

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Solid tumors and metastatic cancers often evade the immune system, rendering localized treatments ineffective at preventing systemic recurrence.

Solution

Immunophotonics develops a proprietary antigen-presenting cell activator designed to turn a routine tumor ablation procedure into a systemic immunotherapy.

Why now

The rapid clinical adoption of interventional oncology procedures has created an immediate opportunity to integrate localized physical therapies with systemic immunotherapeutic agents.

Source: SEC EDGAR Form D filing